BASIL-2
2023
Bypass versus Angioplasty for Severe Ischaemia of the Leg – 2
In 345 patients with chronic limb-threatening ischaemia requiring infra-popliteal revascularisation, a vein-bypass-first strategy worsened amputation-free survival compared with a best-endovascular-treatment-first strategy.
Result
Efficacy: Amputation-free survival (above-ankle amputation or death from any cause)adjusted HR 1.35 (95% CI 1.02-1.80) · P = 0.037
Below 1 favours a vein-bypass-first strategy, above 1 favours a best-endovascular-treatment-first strategy.
- Absolute difference
- 10 points
- NNH
- 10
Absolute difference and NNH are derived from the event rates.
Also reported: Driven mainly by more deaths in the bypass arm (53 % vs 45 %).
- Subtopic
- Revascularisation
- Design
- Open-label, pragmatic phase-3 RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 PAADACC/AHA 2024 PAD
- Source
- Bradbury AW, Moakes CA, et al. Lancet. 2023;401(10390):1798-1809.doi 10.1016/S0140-6736(23)00462-2
Discussion & critique
Small, open-label and driven by all-cause rather than limb-related death, so the mechanism of harm is unclear. Read against BEST-CLI it produces the guideline's nuanced position: anatomy and conduit, not dogma, should decide bypass versus endovascular therapy.